Cancer Treatment Reviews
Volume 26, Issue 6 , Pages 429-447 , December 2000

Long-term chemotherapy-related cardiovascular morbidity

  • M.T. Meinardi

      Affiliations

    • Division of Medical Oncology, Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • J.A. Gietema

      Affiliations

    • Division of Medical Oncology, Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • D.J. van Veldhuisen

      Affiliations

    • Department of Cardiology, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • W.T.A. van der Graaf

      Affiliations

    • Division of Medical Oncology, Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • E.G.E. de Vries

      Affiliations

    • Division of Medical Oncology, Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands
    • ,
  • D.T. Sleijfer

      Affiliations

    • Division of Medical Oncology, Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands

References 

    REFERENCES
  1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–905
  2. Becker K, Erckenbrecht JF, Haussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57:475–484
  3. Lipshultz SE, Colan SD, Gelber RD. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–815
  4. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672–1677
  5. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol. 1995;24:352–361
  6. Vokes EE. Combined modality therapy of solid tumours. Lancet. 1997;349 (Suppl. 2):S114–S116
  7. J Clin Oncol. 1997;15:594–603
  8. Einhorn LH. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1981;41:3275–3280
  9. Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med. 1981;305:727–731
  10. Williams SD, Birch R, Einhorn LH. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–1440
  11. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337:242–253
  12. Doll DC, List AF, Greco FA. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105:48–51
  13. Icli F, Karaoguz H, Dincol D. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587–593
  14. Rodriguez J, Collazos J, Gallardo M, Hernando G. Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer. Ann Pharmacother. 1995;29:138–139
  15. Samules BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987;19:253–256
  16. Gerl A, Clemm C, Schleuning M, Wilmanns W. Fatal cerebrovascular accident associated with chemotherapy for testicular cancer [letter]. Eur J Cancer. 1993;29A:1220–1221
  17. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999;25:47–58
  18. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science. 1980;208:198–200
  19. Lejonc JL, Vernant JP, Macquin J, Castaigne A. Myocardial infarction following vinblastine treatment [letter]. Lancet. 1980;2:692
  20. Airey CL, Dodwell DJ, Joffe JK, Jones WG. Etoposide-related myocardial infarction. Clin Oncol (R Coll Radiol). 1995;7:135
  21. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:2021–2024
  22. Cantwell BM, Mannix KA, Roberts JT, Ghani SE, Harris AL. Thromboembolic events during combination chemotherapy for germ cell- malignancy [letter]. Lancet. 1988;2:1086–1087
  23. Lederman GS, Garnick MB. Pulmonary emboli as a complication of germ cell cancer treatment. J Urol. 1987;137:1236–1237
  24. Hall MR, Richards MA, Harper PG. Thromboembolic events during combination chemotherapy for germ cell malignancy [letter]. Lancet. 1988;2:1259
  25. Jackson AM, Rose BD, Graff LG. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med. 1984;101:41–44
  26. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985;42:296–300
  27. Subar M, Muggia FM. Apparent myocardial ishemia associated with vinblastine administration. Cancer Treat Rep. 1986;70:690–691
  28. Illarramendi JJ, Gallego J. Cisplatin-based chemotherapy and acute cerebrovascular events [letter]. Lancet. 1991;338:705
  29. Gerl A, Clemm C, Wilmanns W. Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer [letter]. Lancet. 1991;338:385–386
  30. Adamson IY, Bowden DH. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77:185–197
  31. Sleijfer S, van der Mark TW, Schraffordt KH, Mulder NH. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer. 1995;71:120–123
  32. Van Barneveld PW, Sleijfer DT, van der Mark TW. Natural course of bleomycin-induced pneumonitis. A follow-up study. Am Rev Respir Dis. 1987;135:48–51
  33. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol. 1986;4:1405–1417
  34. Dirix LY, Libura M, Libura J. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs. 1997;8:859–868
  35. Phan SH, Gharee-Kermani M, Wolber F, Ryan US. Bleomycin stimulates production of transforming growth factor-beta by rat pulmonary artery endothelial cells. Chest. 1991;99:S66
  36. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32:219–226
  37. Pedrinelli R, Giampietro O, Carmassi F. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14–18
  38. Meinardi MT, Gietema JA, van Veldhuisen DJ. Treatment related cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18:1725–1732
  39. Bellmunt J, Navarro M, Morales S. Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity. Cancer. 1990;65:303–309
  40. Boyer M, Raghavan D. Toxicity of treatment of germ cell tumors. Semin Oncol. 1992;19:128–142
  41. Altura BM, Altura BT, Gebrewold A, Ising H, Gunther T. Magnesium deficiency and hypertension: correlation between magnesium- deficient diets and microcirculatory changesin situ. Science. 1984;223:1315–1317
  42. Rayssiguier Y, Mbega JD, Durlach V. Magnesium and blood pressure. I. Animal studies. Magnes Res. 1992;5:139–146
  43. Durlach J, Durlach V, Rayssiguier Y, Bara M, Guiet-Bara A. Magnesium and blood pressure. II. Clinical studies. Magnes Res. 1992;5:147–153
  44. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer. 1985;56:2765–2770
  45. Edwards GS, Lane M, Smith FE. Long-term treatment with cis-dichlorodiammineplatinum(II)-vinblastine-bleomycin: possible association with severe coronary artery disease [letter]. Cancer Treat Rep. 1979;63:551–552
  46. Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol. 1988;6:1239–1247
  47. Stoter G, Koopman A, Vendrik CP. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol. 1989;7:1099–1104
  48. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996;14:2923–2932
  49. Gietema JA, Sleijfer DTh, Willemse PHB. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med. 1992;116:709–715
  50. Belch J. Raynaud’s phenomenon. Cardiovasc Res. 1997;33:25–30
  51. Teutsch C, Lipton A, Harvey HA. Raynaud’s phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep. 1977;61:925–926
  52. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288–292
  53. Aass N, Kaasa S, Lund E. Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer. 1990;61:151–155
  54. Boyer M, Raghavan D, Harris PJ. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol. 1990;8:21–26
  55. Bissett D, Kunkeler L, Zwanenburg L. Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer. 1990;62:655–659
  56. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A:2229–2238
  57. Adoue D, Arlet P. Bleomycin and Raynaud’s phenomenon [letter]. Ann Intern Med. 1984;100:770
  58. Chernicoff DP, Bukowski RM, Young JR. Raynaud’s phenomenon after bleomycin treatment [letter]. Cancer Treat Rep. 1978;62:570–571
  59. Fossa SD, Lehne G, Heimdal K, Theodorsen L. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology. 1995;52:300–305
  60. Hansen SW, Olsen N. Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol. 1989;7:940–942
  61. van Basten JP, Hoekstra HJ, van Driel MF. Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy. J Clin Oncol. 1997;15:2442–2448
  62. Hansen SW, Groth S, Daugaard G, Rossing N, Rorth M. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol. 1988;6:1728–1731
  63. Harrell RM, Sibley R, Vogelzang NJ. Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin. Am J Med. 1982;73:429–433
  64. Wright LF, Reese EP, Bicknell SL. Renovascular hypertension after combination chemotherapy for testicular cancer. J Urol. 1988;139:134–135
  65. Bosl GJ, Leitner SP, Atlas SA. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol. 1986;4:1684–1689
  66. Nichols CR, Roth BJ, Williams SD. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol. 1992;10:760–765
  67. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–318
  68. Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol. 1992;10:1386–1389
  69. Umeki S. Decreases in serum cholesterol levels in advanced lung cancer. Respiration. 1993;60:178–181
  70. Forones NM, Falcao JB, Mattos D, Barone B. Cholesterolemia in colorectal cancer. Hepatogastroenterology. 1998;45:1531–1534
  71. Henriksson P, Eriksson M, Ericsson S. Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet. 1989;2:1178–1180
  72. Shiroeda O, Yamaguchi N, Kawai K. Stimulation of low density lipoprotein receptor activity by conditioned medium from a human cancer cell line. Cancer Res. 1987;47:4630–4633
  73. Ueyama Y, Matsuzawa Y, Yamashita S. Hypocholesterolaemic factor from gallbladder cancer cells. Lancet. 1990;336:707–709
  74. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer. 1996;73:1108–1114
  75. Bosl GJ, Bajorunas D. Pituitary and testicular hormonal function after treatment for germ cell tumours. Int J Androl. 1987;10:381–384
  76. Haffner SM, Mykkanen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab. 1993;77:1610–1615
  77. Hansen SW, Berthelsen JG, von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol. 1990;8:1695–1698
  78. Oppenheim DS, Greenspan SL, Zervas NT, Schoenfeld DA, Klibanski A. Elevated serum lipids in hypogonadal men with and without hyperprolactinemia. Ann Intern Med. 1989;111:288–292
  79. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097–1105
  80. Simon D, Preziosi P, Barrett-Connor E. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia. 1992;35:173–177
  81. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet. 1988;2:530–533
  82. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  83. DeVita VT, Hubbard SM. Hodgkin’s disease. N Engl J Med. 1993;328:560–565
  84. Henry-Amar M, Joly F. Late complications after Hodgkin’s disease. Ann Oncol. 1996;7:115–126
  85. DeVita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73:881–895
  86. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev. 1982;9:21–35
  87. Fisher RI, Gaynor ER, Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006
  88. Miller TP, Dahlberg S, Cassady JR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–26
  89. Klencke B, Kaplan L. Advances and future challenges in non-Hodgkin’s lymphoma. Curr Opin Oncol. 1998;10:422–427
  90. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline. antibiotic cardiotoxicity. Cancer Treat Rep. 1978;62:873–879
  91. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47–58
  92. Laufman LR, Jones JJ, Morrice B. Case report of a lethal cardiac toxic effect following high-dose cyclophosphamide [letter]. J Natl Cancer Inst. 1995;87:539–540
  93. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs. 1991;42:781–795
  94. Tulleken JE, Kooiman CG, van der Werf TS, Zijlstra JG, de Vries EG. Constrictive pericarditis after high-dose chemotherapy [letter]. Lancet. 1997;350:1601
  95. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758–763
  96. Steinherz LJ, Steinherz PG, Mangiacasale D. Cardiac changes with cyclophosphamide. Med Pediatr Oncol. 1981;9:417–422
  97. Isberg B, Paul C, Jonsson L, Svahn U. Myocardial toxicity of high-dose cyclophosphamide in rabbits treated with daunorubicin. Cancer Chemother Pharmacol. 1991;28:171–180
  98. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9:1215–1223
  99. Cazin B, Gorin NC, Laporte JP. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer. 1986;57:2061–2069
  100. House KW, Simon SR, Pugh RP. Chemotherapy-induced myocardial infarction in a young man with Hodgkin’s disease. Clin Cardiol. 1992;15:122–125
  101. Scholz KH, Herrmann C, Tebbe U. Myocardial infarction in young patients with Hodgkin’s disease—potential pathogenic role of radiotherapy, chemotherapy, and splenectomy. Clin Investig. 1993;71:57–64
  102. Hirsch A, Vander EN, Straus DJ. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol. 1996;14:1297–1305
  103. Seifter EJ, Young RC, Longo DL. Deep venous thrombosis during therapy for Hodgkin’s disease. Cancer Treat Rep. 1985;69:1011–1013
  104. Clarke CS, Otridge BW, Carney DN. Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin’s lymphoma. Cancer. 1990;66:2027–2030
  105. Von Hoff DD, Layard MW, Basa P. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717
  106. Gottlieb SL, Edmiston WA, Haywood LJ. Late, late doxorubicin cardiotoxicity. Chest. 1980;78:880–882
  107. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25:72–85
  108. Ghielmini M, Zappa F, Menafoglio A. The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic. Ann Oncol. 1999;10:533–537
  109. Santoro A, Bonadonna G, Valagussa P. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5:27–37
  110. Viviani S, Bonadonna G, Santoro A. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol. 1996;14:1421–1430
  111. Salloum E, Tanoue LT, Wackers FJ. Assessment of cardiac and pulmonary function in adult patients with Hodgkin’s disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. Cancer Invest. 1999;17:171–180
  112. Aviles A, Arevila N, Diaz Maqueo JC. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin’s disease in adults. Leuk Lymphoma. 1993;11:275–279
  113. Haddy TB, Adde MA, McCalla J. Late effects in long-term survivors of high-grade non-Hodgkin’s lymphomas. J Clin Oncol. 1998;16:2070–2079
  114. Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review. Am J Med. 1986;80:483–485
  115. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy—risk factors. Cancer. 1977;39:1397–1402
  116. LaMonte CS, Yeh SD, Straus DJ. Long-term follow-up of cardiac function in patients with Hodgkin’s disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin. Cancer Treat Rep. 1986;70:439–444
  117. Brice P, Tredaniel J, Monsuez JJ. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin’s disease. Ann Oncol. 1991;2:73–76
  118. Benoff LJ, Schweitzer P. Radiation therapy-induced cardiac injury. Am Heart J. 1995;129:1193–1196
  119. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270:1949–1955
  120. Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer. 1992;69:1241–1247
  121. Henry-Amar M, Hayat M, Meerwaldt JH. Causes of death after therapy for early stage Hodgkin’s disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. Int J Radiat Oncol Biol Phys. 1990;19:1155–1157
  122. Wagenvoort CA. Pulmonary veno-occlusive disease. Entity or syndrome?. Chest. 1976;69:82–86
  123. Lombard CM, Churg A, Winokur S. Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest. 1987;92:871–876
  124. Rose AG. Pulmonary veno-occlusive disease due to bleomycin therapy for lymphoma. Case reports. S Afr Med J. 1983;64:636–638
  125. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89:157–161
  126. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–1811
  127. Sourander L, Rajala T, Raiha I. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet. 1998;352:1965–1969
  128. Suda Y, Ohta H, Makita K. Influence of bilateral oophorectomy upon lipid metabolism. Maturitas. 1998;29:147–154
  129. Farish E, Fletcher CD, Hart DM, Smith ML. Effects of bilateral oophorectomy on lipoprotein metabolism. Br J Obstet Gynaecol. 1990;97:78–82
  130. Bruschi F, Meschia M, Soma M. Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet Gynecol. 1996;88:950–954
  131. Munker R, Cremer P, Fries S, Hiller E. Serum lipids in patients with Hodgkin’s disease in complete remission. Acta Oncol. 1997;36:75–77
  132. Bonadonna G, Brusamolino E, Valagussa P. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–410
  133. Misset JL, di Palma M, Delgado M. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol. 1996;14:1136–1145
  134. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989;12:123–128
  135. Fisher B, Brown AM, Dimitrov NV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483–1496
  136. Coombes RC, Bliss JM, Wils J. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol. 1996;14:35–45
  137. Levine MN, Bramwell VH, Pritchard KI. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:2651–2658
  138. Sasson Z, Morgan CD, Wang B. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol. 1994;10:861–864
  139. Millart H, Brabant L, Lorenzato M. The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart. Anticancer Res. 1992;12:571–576
  140. Chaudary S, Song SY, Jaski BE. Profound, yet reversible, heart failure secondary to 5-fluorouracil. Am J Med. 1988;85:454–456
  141. Jakubowski AA, Kemeny N. Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. Cancer. 1988;62:266–269
  142. Schober C, Papageorgiou E, Harstrick A. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 1993;72:2242–2247
  143. Coronel B, Madonna O, Mercatello A, Caillette A, Moskovtchenko JF. Myocardiotoxicity of 5 fluorouracil. Intensive Care Med. 1988;14:429–430
  144. Weidmann B, Jansen W, Heider A, Niederle N. 5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. Am J Cardiol. 1995;75:194–195
  145. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol. 1990;1:409–414
  146. de Forni M, Malet-Martino MC, Jaillais P. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10:1795–1801
  147. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol. 1996;7:731–737
  148. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer. 1993;71:493–509
  149. Lomeo MN, Avolio C, lacobellis G, Manzione L. 5-Fluorouracil cardiotoxicity. Eur J Gynaecol Oncol. 1990;11:237–241
  150. Levine MN, Gent M, Hirsh J. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404–407
  151. Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981;65:677–679
  152. Nicolson GL, Custead SE. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res. 1985;45:331–336
  153. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985;55:2761–2765
  154. Shapiro CL, Hardenbergh PH, Gelman R. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16:3493–3501
  155. Gianni L, Zambetti M, Moliterni A. Cardiac sequelae in operable breast cancer patients after CMF ± doxorubicin (A) ± irradiation. Proc Am Soc Clin Oncol. 1999;18:68a
  156. Cuzick J, Stewart H, Peto R. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep. 1987;71:15–29
  157. Cuzick J, Stewart H, Rutqvist L. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447–453
  158. Paszat LF, Mackillop WJ, Groome PA. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol. 1998;16:2625–2631
  159. Fuller SA, Haybittle JL, Smith RE, Dobbs HJ. Cardiac doses in post-operative breast irradiation. Radiother Oncol. 1992;25:19–24
  160. Rutqvist LE, Liedberg A, Hammar N, Dalberg K. Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys. 1998;40:359–363
  161. Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet. 1999;354:1425–1430
  162. Valagussa P, Zambetti M, Biasi S. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol. 1994;5:209–216
  163. Blomqvist C, Tiusanen K, Elomaa I. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast-cancer. Long-term follow-up results of a randomised trial. Br J Cancer. 1992;66:1171–1176
  164. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–1729
  165. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab. 1996;81:4453–4457
  166. Love RR, Newcomb PA, Wiebe DA. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82:1327–1332
  167. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534–1539
  168. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ. 1995;311:977–980
  169. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1993;85:1398–1406
  170. Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab. 1998;83:1633–1635
  171. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer. 1994;73:659–663
  172. Colls BM, George PM. Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use. Clin Oncol (R Coll Radiol). 1998;10:270–271
  173. Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J. 1997;44:745–749
  174. Jonkers GH. Tamoxifen and hypertriglyceridemia [letter]. Neth J Med. 1999;55:84–85
  175. N Engl J Med. 1985;312:1465–1472
  176. Fisher B, Wolmark N, Rockette H. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80:21–29
  177. Grandi AM, Pinotti G, Morandi E. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol. 1997;8:705–708
  178. Papamichael D, Amft N, Slevin ML, D’Cruz D. 5-Fluorouracil-induced Raynaud’s phenomenon [letter]. Eur J Cancer. 1998;34:1983
  179. Gianni L, Munzone E, Capri G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688–2699
  180. Gehl J, Boesgaard M, Paaske T, Vittrup JB, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996;7:687–693
  181. Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?. Semin Oncol. 1999;26:96–101
  182. de Wit R, Stoter G, Kaye SB. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15:1837–1843
  183. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs. 1997;54:30–35
  184. Horwich A, Sleijfer DT, Fossa SD. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15:1844–1852
  185. Hensley ML, Schuchter LM, Lindley C. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol. 1999;17:3333–3355
  186. Schwartz RG, McKenzie WB, Alexander J. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109–1118
  187. Steinherz LJ, Graham T, Hurwitz R. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89:942–949
  188. Meinardi MT, van der Graaf WT, van Veldhuisen DJ. Detection of anthracycline- induced cardiotoxicity. Cancer Treat Rev. 1999;25:237–247
  189. N Engl J Med. 1992;327:685–691
  190. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol. 1999;33:916–923
  191. Walsh BW, Kuller LH, Wild RA. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445–1451

PII: S0305-7372(00)90175-0

doi: 10.1053/ctrv.2000.0175

Cancer Treatment Reviews
Volume 26, Issue 6 , Pages 429-447 , December 2000

Article Tools